Azitra posts ex vivo anti-wrinkle, repeat-dose distribution gains for ATR-COSF program
AZTR•Elasticity findings and next steps
Elasticity rose dose-dependently at 20 hours, ranging from 1.6x at 0.09% w/w to 4.4x at 7.5% w/w.
Azitra plans additional ex vivo wrinkle-model testing ahead of a human study aimed at visible wrinkle-reduction outcomes.
Repeat-dose ex vivo results for ATR-COSF
Azitra reported ex vivo repeat-dose results for its ATR-COSF cosmetic program showing increased delivery of rHDfilaggrin into deeper skin layers.
A 2% lyophilized supernatant hydrogel showed greater distribution into the stratum granulosum versus prior single-dose work.
